TY - JOUR
T1 - International trends in antipsychotic use
T2 - A study in 16 countries, 2005–2014
AU - Hálfdánarson, Óskar
AU - Zoëga, Helga
AU - Aagaard, Lise
AU - Bernardo, Miquel
AU - Brandt, Lena
AU - Fusté, Anna Coma
AU - Furu, Kari
AU - Garuoliené, Kristina
AU - Hoffmann, Falk
AU - Huybrechts, Krista F.
AU - Kalverdijk, Luuk J.
AU - Kawakami, Koji
AU - Kieler, Helle
AU - Kinoshita, Takuya
AU - Litchfield, Melisa
AU - López, Soffy C.
AU - Machado-Alba, Jorge E.
AU - Machado-Duque, Manuel E.
AU - Mahesri, Mufaddal
AU - Nishtala, Prasad S.
AU - Pearson, Sallie Anne
AU - Reutfors, Johan
AU - Saastamoinen, Leena K.
AU - Sato, Izumi
AU - Schuiling-Veninga, Catharina C.M.
AU - Shyu, Yu Chiau
AU - Skurtveit, Svetlana
AU - Verdoux, Hélène
AU - Wang, Liang Jen
AU - Yahni, Corinne Zara
AU - Bachmann, Christian J.
N1 - Publisher Copyright:
© 2017 Elsevier B.V. and ECNP
PY - 2017/10
Y1 - 2017/10
N2 - The objective of this study was to assess international trends in antipsychotic use, using a standardised methodology. A repeated cross-sectional design was applied to data extracts from the years 2005 to 2014 from 16 countries worldwide. During the study period, the overall prevalence of antipsychotic use increased in 10 of the 16 studied countries. In 2014, the overall prevalence of antipsychotic use was highest in Taiwan (78.2/1000 persons), and lowest in Colombia (3.2/1000). In children and adolescents (0–19 years), antipsychotic use ranged from 0.5/1000 (Lithuania) to 30.8/1000 (Taiwan). In adults (20–64 years), the range was 2.8/1000 (Colombia) to 78.9/1000 (publicly insured US population), and in older adults (65+ years), antipsychotic use ranged from 19.0/1000 (Colombia) to 149.0/1000 (Taiwan). Atypical antipsychotic use increased in all populations (range of atypical/typical ratio: 0.7 (Taiwan) to 6.1 (New Zealand, Australia)). Quetiapine, risperidone, and olanzapine were most frequently prescribed. Prevalence and patterns of antipsychotic use varied markedly between countries. In the majority of populations, antipsychotic utilisation and especially the use of atypical antipsychotics increased over time. The high rates of antipsychotic prescriptions in older adults and in youths in some countries merit further investigation and systematic pharmacoepidemiologic monitoring.
AB - The objective of this study was to assess international trends in antipsychotic use, using a standardised methodology. A repeated cross-sectional design was applied to data extracts from the years 2005 to 2014 from 16 countries worldwide. During the study period, the overall prevalence of antipsychotic use increased in 10 of the 16 studied countries. In 2014, the overall prevalence of antipsychotic use was highest in Taiwan (78.2/1000 persons), and lowest in Colombia (3.2/1000). In children and adolescents (0–19 years), antipsychotic use ranged from 0.5/1000 (Lithuania) to 30.8/1000 (Taiwan). In adults (20–64 years), the range was 2.8/1000 (Colombia) to 78.9/1000 (publicly insured US population), and in older adults (65+ years), antipsychotic use ranged from 19.0/1000 (Colombia) to 149.0/1000 (Taiwan). Atypical antipsychotic use increased in all populations (range of atypical/typical ratio: 0.7 (Taiwan) to 6.1 (New Zealand, Australia)). Quetiapine, risperidone, and olanzapine were most frequently prescribed. Prevalence and patterns of antipsychotic use varied markedly between countries. In the majority of populations, antipsychotic utilisation and especially the use of atypical antipsychotics increased over time. The high rates of antipsychotic prescriptions in older adults and in youths in some countries merit further investigation and systematic pharmacoepidemiologic monitoring.
KW - Adult
KW - Aged
KW - Antipsychotic agents
KW - Internationality
KW - Minors
KW - Pharmacoepidemiology
UR - http://www.scopus.com/inward/record.url?scp=85026209181&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2017.07.001
DO - 10.1016/j.euroneuro.2017.07.001
M3 - Article
C2 - 28755801
AN - SCOPUS:85026209181
SN - 0924-977X
VL - 27
SP - 1064
EP - 1076
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 10
ER -